Preparation of coaxial electrospinning nanofibers for nerve growth factor delivery
Jian-guang Wang,Jun-jian Liu,Cun-yi Fan,Xiu-mei Mo,Chuang-long He,Feng Chen
DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.23.014
2008-01-01
Abstract:Background: Protein drugs are commonly admixed with organic solvents in traditional fabrication process of sustained release system, which denatures the proteins. Coaxial electrospinning method may reduce the contact between proteins and organic solvents, and is expected to improve the bioactivity of proteins and become a new type drug release system. Objective: To investigate the feasibility of encapsulating protein drug of nerve growth factor (NGF) into the core-shell nanofibers through coaxial electrospinning for sustained release. Design, time and setting: Comparative observation experiments were performed in the Institute of Biological Sciences and Biotechnology, Donghua University (Shanghai, China) from July to December in 2007. Materials: Poly(L-lactide-co-epsilon-caprolactone) [P(LLA-CL), 50:50, Mw=378, 839 g/mol, Mw/Mw=2.732 4] was supplied from Institute of Biological Sciences and Biotechnology, Donghua University (China). Recombinant rat β -NGF was supplied from R&D Systems (USA). Bovine serum albumin (BSA) was purchased from Sigma-Aldrich Inc (USA). Rat pheochromocytoma cell line (PC 12 cells) was obtained from the Cell Bank of Chinese Academy of Sciences (China). Methods: The core-shell structured composite nanofibers with P(LLA-CL) as a shell and BSA/NGF as a core were fabricated through coaxial electrospinning technology. The nanofibers were released in vitro for 8 weeks, and at various time points, the NGF supernatant from the P(LLA-CL)/BSA/NGF fibers was added into serum-free RPMI medium to culture PC12 cells. The nanofibers were divided into three groups according to the core solution flow rate: 0. 10, 0. 15 and 0.25 mL/h. Main outcome measures: Through the images of scanning electron microscopy and transmission electron microscopy, we obtained morphological characters of the nanofibers. The diameter range of the fabricated nanofibers was measured using an image visualization software Image-J. PC 12 cells, which differentiated to neuronal phenotype in the presence of bioactive NGF, were used to test the bioactivity of the NGF released from the electrospun fibers. Results: The core-shell structure of P(LLA-CL)/BSA/NGF nanofibers was achieved by coaxial electrospinning, and the average diameter and diameter range of the nanofibers were increased with the increase of the core solution flow rate. When the core solution flow rate was low as 0.10 or 0.15 mL/h, P(LLA-CL)/BSA/NGF compound had better electrospinnability than the rate was 0.25 mL/h, obtaining the stable and completely "bead-free" nanofibers. PC12 cells could differentiate into neurons and outgrowth neurites in the NGF supernatant from P(LLA-CL)/BSA/NGF nanofibers. It indicated that the released NGF retained some degree of bioactivity for at least 8 weeks. Conclusion: It is feasible to encapsulate protein drug NGF into core-shell nanofibers through coaxial electrospinning technology for sustained release.